Using synthetic biology to address iron deficiency in south and southeast Asia
Reference number | |
Coordinator | IRONIC AB |
Funding from Vinnova | SEK 77 735 |
Project duration | November 2024 - March 2025 |
Status | Completed |
Venture | Emerging technology solutions |
Call | Innovative collaborations with Singapore in quantum or synthetic biology |
Important results from the project
Yes, this initial project has produced the expected results. We confirmed that low iron status is prevalent. Meetings with leadership teams in food and nutrition highlighted that one-third of females are affected by iron deficiency and anemia, similar to Europe and the Americas. IRONIC is engaging with key players in Singapore, with plans for regional expansion. This partnership will support R&D connections, regulatory navigation, and commercialization of IRONIC proteins.
Expected long term effects
In the long term, we envision IRONIC proteins being commercialized in Singapore and integrated into common regional foods. Additionally, we anticipate the development of novel probiotics and supplements in collaboration with leading players in the region. These efforts aim to mitigate iron deficiency and anaemia, along with their detrimental effects.
Approach and implementation
The project has been divided into three phases: Preparation Phase: In Sweden, we reviewed literature on iron deficiency in Singapore, identified potential partners, and scheduled meetings. Engagement Phase: In Singapore, we met pre-arranged contacts and new individuals encountered during our stay. Follow-up Phase: Back in Sweden, we followed up on discussions and are working on strategic collaborations with identified partners.